Vical Incorporated’s Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi Pasteur Fluzone(R) Seasonal Influenza Vaccine

SAN DIEGO, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the publication of two articles regarding the company’s Vaxfectin(R) adjuvant in a special issue of Vaccine.(1,2) One article highlighted preclinical data showing Vaxfectin(R)'s improvement of performance with Sanofi-Pasteur Fluzone(R) seasonal influenza vaccine; the other analyzed how Vaxfectin(R) works.